Neurocrine Biosciences NBIX Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Neurocrine Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Neurocrine Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Neurocrine Biosciences's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Neurocrine Biosciences's stock-based comp?
- Neurocrine Biosciences (NBIX) reported stock-based comp of $57.2M in Q1 2026.
- How has Neurocrine Biosciences's stock-based comp changed year-over-year?
- Neurocrine Biosciences's stock-based comp increased by 8.3% year-over-year, from $52.8M to $57.2M.
- What is the long-term trend for Neurocrine Biosciences's stock-based comp?
- Over 4 years (2021 to 2025), Neurocrine Biosciences's stock-based comp has grown at a 12.9% compound annual growth rate (CAGR), from $134.2M to $217.9M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.